# A Study to Assess the Bioequivalence of Follitropin Alfa Solution in Pen and Follitropin Alfa Powder in Vial in Healthy Downregulated Male Participants

> **NCT07097259** · PHASE1 · COMPLETED · sponsor: **EMD Serono Research & Development Institute, Inc.** · enrollment: 55 (actual)

## Conditions studied

- Hypogonadism

## Interventions

- **COMBINATION_PRODUCT:** Test: Follitropin alfa
- **DRUG:** Reference: Follitropin alfa
- **DRUG:** Zoladex

## Key facts

- **NCT ID:** NCT07097259
- **Lead sponsor:** EMD Serono Research & Development Institute, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-07-21
- **Primary completion:** 2025-12-23
- **Final completion:** 2025-12-23
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2026-02-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07097259

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07097259, "A Study to Assess the Bioequivalence of Follitropin Alfa Solution in Pen and Follitropin Alfa Powder in Vial in Healthy Downregulated Male Participants". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07097259. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*